Type 1/like CALR mutation in momelotinib-treated patients with myelofibrosis is the most prominent predictor of drug survival and longevity without transplant

Data presented during the 2023 American Society of Hematology Annual Meeting supports that CALR-1 mutation is the most important risk factor for both drug survival and longevity without allogeneic hematopoietic stem cell transplant among patients with myelofibrosis previously treated with momelotinib. The 3-, 5-, and 10-year drug survival rates for patients with CALR-1-mutated disease were 64%, 40%, and 18%, respectively, and for CALR-1 wild-type 25%, 11%, and 4% (p=0.01).